Agilent Technologiesvs.Revvity
A vs RVTY · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Agilent Technologies is about 2.8× larger than Revvity by market cap; Agilent Technologies trades at the lower P/E (33.3 vs 72.6); year to date, Revvity leads (+57.3% vs +24.3%).
Side by side
| A | RVTY | |
|---|---|---|
| Market cap | $48B | $17.2B |
| Price | $170.54 | $154.18 |
| Today | +1.4% | +1.3% |
| Return YTD | +24.3% | +57.3% |
| Return 1Y | +22.0% | +65.8% |
| Since June 26, 2026 | +25.4% | +36.4% |
| P/E | 33.3 | 72.6 |
| P/S | 6.5 | 5.9 |
| P/B | 6.5 | 2.4 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Agilent TechnologiesA
Laboratory analysis is the business: LC/MS and other analytical instruments, sold with the consumables and diagnostic reagents that keep them running.
Full A profile →RevvityRVTY
Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.
Full RVTY profile →More A & RVTY comparisons
Other head-to-heads in the Life science tools segment.